



RECEIVED

JUL 11 2002

1623

EE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
TECH CENTER 2000

In re Application of:

Seeberger P. H. et al.

Application No.: 10/054,724

Filed: January 22, 2002

For: Solid-and Solution-Phase Synthesis of
Heparin and Other Glycosaminoglycans

Examiner: To Be Assigned


Art Unit: 1623

Attorney Document No.: MTV-037.01

(20021-3701)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on: July 11, 2002



Kristen Willett

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97 (b)(3)

Commissioner for Patents
Washington, DC 20231

Sir:

In compliance with the requirements of 37 C.F.R. 1.56 and 1.97(b)(3), submitted herewith on Form PTO-1449 is a list of publications known to Applicants and their Attorney/Agent. A copy of each publication is also being submitted herewith. Applicants respectfully request that the Examiner consider the listed publication and indicate they were considered by making appropriate notations on the attached Form 1449.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that the cited documents are material or constitute "prior art." If the Examiner applies the listed documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law

regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the referenced documents be applied against the claims of the present application.

Under 37 C.F.R. § 1.97 (b)(3), this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits; therefore, no fee is believed to be due in connection with this submission. However, the Commissioner is authorized to charge any deficiencies or credit any overpayment to/from our **Deposit Account, No. 06-1448.**

Respectfully Submitted,

Date: July 1, 2002

Customer No.: 25181
Patent Group
Foley Hoag LLP
155 Seaport Boulevard
Boston, MA 02210



Dana M. Gordon, PhD
Reg. No. 44,719
Attorney for Applicants